Creating advanced biologics for targeted cancer treatment
Official title: Development of next-generation biologics programmed with multifunctional synthetic chemistries
Funded at Pearl Bio, INC. · NIH-10823892 · Data updated 2026-11-12
This study is working on creating new types of proteins that can be customized to better treat diseases like cancer and multiple sclerosis, making them safer and more effective for patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pearl Bio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | March 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $274,692 |
| NIH project number | 1R43GM150368-01A1 |
| Project ID | NIH-10823892 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancer or other conditions that could benefit from advanced biologic therapies.
✕Less likely to help
Patients with conditions not related to cancer or those who do not respond to biologic therapies may not benefit from this research.
What this research studies
This research focuses on developing next-generation biologics, specifically cytokine proteins, that can be engineered to improve their effectiveness in treating diseases like cancer and multiple sclerosis. The approach aims to overcome current limitations such as rapid degradation and systemic immune activation by creating multifunctional proteins that can be tailored for better specificity and longer-lasting effects in the body. By utilizing innovative synthetic biology techniques, the goal is to enhance the therapeutic potential of these biologics, making them safer and more effective for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for cancer and other serious diseases.
How similar studies have gone: Previous research has shown promise in developing biologics with enhanced properties, but this approach aims to address specific challenges that have not been fully resolved in earlier studies.
Where this research is happening
-
Pearl Bio, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Chattopadhyay, Souvik — Pearl Bio, INC.
- Study coordinator: Chattopadhyay, Souvik
Related research
Other NIH-funded projects on the same topics.
-
Creating advanced nanobodies for targeted cancer therapy
This study is working on creating tiny antibodies that can deliver cancer-fighting drugs right to tumors, making treatments more effective and with fewer side effects, so patients can have better options for fighting cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.